홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

Iomeprol

HCID 3731
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
78649-41-9
표준 SMILES
CN(C(=O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I
InChIKey
NJKDOADNQSYQEV-UHFFFAOYSA-N
분자식
C17H22I3N3O8
평균 분자량
777.1 g/mol
단동위원소 질량
776.8541

개요

Iomeprol is a benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a glycoloyl(methyl)amino group at the 5-position. It has a role as a xenobiotic, a radioopaque medium and an environmental contaminant. It is an organoiodine compound and a benzenedicarboxamide.

이름 및 식별자

우선 이름
Iomeprol
IUPAC
1-N,3-N-bis(2,3-dihydroxypropyl)-5-[(2-hydroxyacetyl)-methylamino]-2,4,6-triiodobenzene-1,3-dicarboxamide
영어명
IOMEPROL
분자식
C17H22I3N3O8
분자량
777.09

이름 및 동의어

iomeprol78649-41-9IomeronIomeprolumIomeproloDTXSID1049061Iomeron 300IOMERVUE-7337N,N'-Bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-(N-methylglycolamido)isophthalamide17E17JBP8LDTXCID2028987
이름 더 보기
Iomepol.Iomeron 350ImeronImeron 300Iomeprogr.Iomeprol materialIOMEPROL USP/EP/BPC14348000 Iomeprol
E7337CHEBI:31710N,N'-bis(2,3-dihydroxypropyl)-5-[glycoloyl(methyl)amino]-2,4,6-triiodoisophthalamide1,3-Benzenedicarboxamide, N,N'-bis(2,3-dihydroxypropyl)-5-((hydroxyacetyl)methylamino)-2,4,6-triiodo-Iomeprol InjectionN,N'-bis(2,3-dihydroxypropyl)-5-(glycoloyl(methyl)amino)-2,4,6-triiodoisophthalamideRefChem:57671V08AB10

데이터베이스 식별자

CAS
78649-41-9
PubChem CID
3731
DTXSID
DTXSID1049061
ChEMBL
CHEMBL2107214
ChEBI
CHEBI:31710

물성

구조 계산 물성

XLogP
-2.3
극성 표면적
180 Ų
수소 결합 공여자 수
7
수소 결합 수용자 수
8
회전 가능 결합 수
10
무거운 원자 수
31
형식 전하
0
복잡도
591

실험 및 물리화학적 성질

DrugsPharmaceuticals
Human Drugs · 3건

Breast Feeding; Lactation; Milk, Human; Contrast Media; Diagnostic Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point285-291
Collision Cross Section211.2 Ų [M-H]-

물리화학적 성질

녹는점
263 · 263-265C
끓는 점
813.2 · 813.2±65.0 °C(Predicted)
밀도
420 · d420 1.166; d437 1.161; d420 1.334; d437 1.329; d420 1.446; d437 1.441
굴절률
20 · nD20 1.3828; nD20 1.4327; nD20 1.4660
저장 조건
-20 °C · -20°C Freezer
용해도
DMSO(약간 용해됨), 메탄올(약간 용해됨)
산도 계수 (pKa)
11.36 · 11.36±0.46(Predicted)
물리적 상태
고체
색상
흰색에서 황백색까지
InChI
InChI=1S/C17H22I3N3O8/c1-23(9(29)6-26)15-13(19)10(16(30)21-2-7(27)4-24)12(18)11(14(15)20)17(31)22-3-8(28)5-25/h7-8,24-28H,2-6H2,1H3,(H,21,30)(H,22,31)

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

독성 정보

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

안전 데이터

독성
LD50 (400 mgI/ml soln) i.v. in mice, rats (gI/kg): 19.9, 14.5; LD50 (370 mgI/ml soln) i.v. in dogs (gI/kg): >12.5 (Morisetti)
HS 번호
2924299090

화학 및 산업

약리 정보

ATC Code · 3건

V08AB10

V - Various

QV - Various

Protein BindingIomeprol does not bind to plasma proteins.
Pharmacodynamics · 1건

The degree of radiographic enhancement by iomeprol is related to the iodine concentration in the tissue of interest following the administration of iomeprol. However, the exposure-response relationships and time course of pharmacodynamic response of iomeprol have not been fully characterized. At therapeutic concentrations, iomeprol was not shown to cause significant effects on the cardiovascular, central nervous, renal, and complement systems.

Mechanism of Action · 1건

Iomeprol is a radiographic iodinated contrast agent that opacifies the vessels and body structures where the contrast agent is present following intravenous or intra-arterial administration, permitting radiographic visualization of the internal structures through attenuation of X-ray photons. In imaging of the body, iodinated contrast agents diffuse from the vessels into the extravascular space. In normal brain with an intact blood-brain barrier, the contrast agent does not diffuse into the extravascular space and contrast enhancement is generally due to the presence of contrast within the vascular space. In patients with a disrupted blood-brain barrier, the contrast agent accumulates in the extravascular space in the region of disruption.

Biological Half-LifeThe elimination half-life of iomeprol is 1.8 (0.33) hours.
Metabolism/MetabolitesIomeprol does not undergo significant metabolism.
FDA Pharmacological Classification · 6건

17E17JBP8L

IOMEPROL

Established Pharmacologic Class [EPC] - Radiographic Contrast Agent

Mechanisms of Action [MoA] - X-Ray Contrast Activity

Iomeprol is a Radiographic Contrast Agent. The mechanism of action of iomeprol is as a X-Ray Contrast Activity.

관련 반응

0건
반응 기록 만들기
아직 관련 반응이 없습니다

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
UNII
17E17JBP8L
Nikkaji
J277.762B
InChIKey
NJKDOADNQSYQEV-UHFFFAOYSA-N
SMILES
C1(C(NCC(O)CO)=O)=C(I)C(N(C(CO)=O)C)=C(I)C(C(NCC(O)CO)=O)=C1I
EPA
1 · 1,3-Benzenedicarboxamide, N1,N3-bis(2,3-dihydroxypropyl)-5-[(2-hydroxyacetyl)methylamino]-2,4,6-triiodo- (78649-41-9)

화학적 성질

White Solid

IOMEPROL INJECTION

MeSH Pharmacological ClassificationSubstances used to allow enhanced visualization of tissues.
Absorption, Distribution and Excretion · 4건

The maximum concentration (Cmax) and area under the concentration-time curve (AUC) are doseproportional across the dose range of 250 mg iodine/kg to 1,250 mg iodine/kg body weight.

Approximately 90% of the iomeprol dose is excreted unchanged in urine within 24 hours.

The volume of distribution of iomeprol is 0.28 (0.05) L/kg. In rats, iomeprol was shown to cross the placenta and be excreted into breast milk.

The total body clearance is 0.10 (0.01) L/hr/kg.

용도 및 제조

UsesUse (kg) in Switzerland (2009): >1000

상·하류 제품 정보

상류 원료

5-AMino-N,N'-비스(2,3-디히드록시프로필)-2,4,6-트리요오도-1,3-벤젠디카르복사미드테트라아세테이트5-Amino-2,4,6-triiodoisophthaloyl dichloride5-Amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamideN-DesMethylIo메프롤5-[[2-(아세틸옥시)아세틸]아미노]-2,4,6-트리요오도-1,3-벤젠디카르보닐디클로라이드5-아미노아이소프탈산디메틸설페이트요오드 메탄

추가 설명

정의ChEBI: A benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a glycoloyl(methyl)amino group at the 5-position.